bullish

Astellas Pharma (4503 JP): US Momentum Drives 1HFY25 Result; Guidance Revised Upward

177 Views31 Oct 2024 17:05
​Astellas Pharma reported 22% revenue growth in H1FY25 driven by Xtandi sales The company raises guidance for FY25 with Xtandi and Padcev being key drivers of future growth, contributing 57% revenue.
What is covered in the Full Insight:
  • Introduction
  • Financial Highlights
  • Product Performance
  • Guidance and Outlook
  • Market and Competitive Analysis
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
x